Different regulation of MHC Class I antigen processing components in human tumors

References

• Alpan, R. S., Zhang, M., Pardee, A. B. 1996. Cell cycle-dependent expression of TAP1, TAP2, and HLA-B27 messenger RNAs in a human breast cancer cell line. Cancer Res. 56:4358–4361.
   PubMed Web of Science ®Google Scholar
• Aptsiauri, N., Cabrera, T., Mendez, R., Garcia-Lora, A., Ruiz-Cabello, F., Garrido, F. 2007. Role of altered expression of HLA Class I molecules in cancer progression. Adv. Exp. Med. Biol. 601:123–131.
   PubMed Web of Science ®Google Scholar
• Atkins, D., Breuckmann, A., Schmahl, G. E., Binner, P., Ferrone, S., Krummenauer, F., Storkel, S., Seliger, B. 2004a. MHC Class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int. J. Cancer 109:265–273.
   PubMed Web of Science ®Google Scholar
• Atkins, D., Ferrone, S., Schmahl, G. E., Storkel, S., Seliger, B. 2004b. Down-regulation of HLA Class I antigen-processing molecules: An immune escape mechanism of renal cell carcinoma? J. Urol. 171:885–889.
   PubMed Web of Science ®Google Scholar
• Bangia, N., Ferrone, S. 2006. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: Do they provide tumor cells with escape mechanisms from recognition by cytotoxic T-lymphocytes? Immunol. Invest. 35:485–503.
   PubMed Web of Science ®Google Scholar
• Bui, J. D., Schreiber, R. D. 2007. Cancer immunosurveillance, immunoediting, and inflammation: Independent or interdependent processes? Curr. Opin. Immunol. 19:203–208.
   PubMed Web of Science ®Google Scholar
• Cabrera, C. M. 2007. The double role of the endoplasmic reticulum chaperone tapasin in peptide optimization of HLA Class I molecules. Scand. J. Immunol. 65:487–493.
   PubMed Web of Science ®Google Scholar
• Cabrera, T., Maleno, I., Collado, A., Lopez Nevot, M. A., Tait, B. D., Garrido, F. 2007. Analysis of HLA Class I alterations in tumors: Choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 69(S1):264–268.
   PubMedGoogle Scholar
• Chang, C. C., Ferrone, S. 2007. Immune selective pressure and HLA Class I antigen defects in malignant lesions. Cancer Immunol. Immunother. 56:227–236.
   PubMed Web of Science ®Google Scholar
• Chang, C. C., Campoli, M., Ferrone, S. 2003. HLA Class I defects in malignant lesions: What have we learned? Keio. J. Med. 52:220–229.
   PubMedGoogle Scholar
• Chang, C. C., Ogino, T., Mullins, D. W., Oliver, J. L., Yamshchikov, G. V., Bandoh, N., Slingluff, C. L., Jr., Ferrone, S. 2006. Defective human leukocyte antigen Class I-associated antigen presentation caused by a novel β2-microglobulin loss-of-function in melanoma cells. J. Biol. Chem. 281:18763–18773.
   PubMed Web of Science ®Google Scholar
• Chen, H. L., Gabrilovich, D., Tampe, R., Girgis, K. R., Nadaf, S., Carbone, D. P. 1996. A functionally-defective allele of TAP1 results in loss of MHC Class I antigen presentation in a human lung cancer. Nat. Genet. 13:210–213.
   PubMed Web of Science ®Google Scholar
• Deng, X. L., Chen, W., Cai, M. Y., Wei, D. P. 2003. Expression of Class I MHC molecule, HSP70 and TAP in human hepatocellular carcinoma. World J. Gastroenterol. 9:1853–1855.
   PubMedGoogle Scholar
• Dunn, G. P., Ikeda, H., Bruce, A. T., Koebel, C., Uppaluri, R., Bui, J., Chan, R., Diamond, M., White, J. M., Sheehan, K. C., Schreiber, R. D. 2005. Interferon-γ and cancer immunoediting. Immunol Res. 32:231–245.
   PubMed Web of Science ®Google Scholar
• Dunn, G. P., Old, L. J., Schreiber, R. D. 2004a. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148.
   PubMed Web of Science ®Google Scholar
• Dunn, G. P., Old, L. J., Schreiber, R. D. 2004b. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22:329–360.
   PubMed Web of Science ®Google Scholar
• Fruci, D., Ferracuti, S., Limongi, M. Z., Cunsolo, V., Giorda, E., Fraioli, R., Sibilio, L., Carroll, O., Hattori, A., van Endert, P. M., Giacomini, P. 2006. Expression of endoplasmic reticulum aminopeptidases in EBV-B cell lines from healthy donors and in leukemia/ lymphoma, carcinoma, and melanoma cell lines. J. Immunol. 176:4869–4879.
   PubMed Web of Science ®Google Scholar
• Garcia-Lora, A., Algarra, I., Garrido, F. 2003. MHC Class I antigens, immune surveillance, and tumor immune escape. J. Cell. Physiol. 195:346–355.
   PubMed Web of Science ®Google Scholar
• Hammer, G. E., Kanaseki, T., Shastri, N. 2007. The final touches make perfect the peptide-MHC Class I repertoire. Immunity 26:397–406.
   PubMed Web of Science ®Google Scholar
• Jensen, P. E. 2007. Recent advances in antigen processing and presentation. Nat. Immunol. 8:1041–1048.
   PubMed Web of Science ®Google Scholar
• Jimenez, P., Canton, J., Collado, A., Cabrera, T., Serrano, A., Real, L. M., Garcia, A., Ruiz-Cabello, F., Garrido, F. 1999. Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. Int. J. Cancer 83:91–97.
   PubMed Web of Science ®Google Scholar
• Kurte, M., Lopez, M., Aguirre, A., Escobar, A., Aguillon, J. C., Charo, J., Larsen, C. G., Kiessling, R., Salazar-Onfray, F. 2004. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC Class I and transporter associated with antigen processing 1/2 in human melanoma cells. J. Immunol. 173:1731–1737.
   PubMed Web of Science ®Google Scholar
• Li, J., Schuler-Thurner, B., Schuler, G., Huber, C., Seliger, B. 2001. Bipartite regulation of different components of the MHC Class I antigen-processing machinery during dendritic cell maturation. Int. Immunol. 13:1515–1523.
   PubMed Web of Science ®Google Scholar
• Maleno, I., Cabrera, C. M., Cabrera, T., Paco, L., Lopez-Nevot, M. A., Collado, A., Ferron, A., Garrido, F. 2004. Distribution of HLA Class I altered phenotypes in colorectal carcinomas: High frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Immunogenetics 56:244–253.
   PubMed Web of Science ®Google Scholar
• Manning, J., Indrova, M., Lubyova, B., Pribylova, H., Bieblova, J., Hejnar, J., Simova, J., Jandlova, T., Bubenik, J., Reinis, M. 2008. Induction of MHC Class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours. Immunology 123:218–227.
   PubMed Web of Science ®Google Scholar
• Meissner, M., Reichert, T. E., Kunkel, M., Gooding, W., Whiteside, T. L., Ferrone, S., Seliger, B. 2005. Defects in the human leukocyte antigen Class I antigen processing machinery in head and neck squamous cell carcinoma: Association with clinical outcome. Clin. Cancer Res. 11:2552–2560.
   PubMed Web of Science ®Google Scholar
• Mendez, R., Rodriguez, T., Del Campo, A., Monge, E., Maleno, I., Aptsiauri, N., Jiménez, P., Pedrinaci, S., Pawelec, G., Ruiz-Cabello, F., Garrido, F. 2008. Characterization of HLA Class I altered phenotypes in a panel of human melanoma cell lines. Cancer Immunol. Immunother. 57:719–729.
   PubMed Web of Science ®Google Scholar
• Nie, Y., Yang, G., Song, Y., Zhao, X., So, C., Liao, J., Wang, L. D., Yang, C. S. 2001. DNA hypermethylation is a mechanism for loss of expression of the HLA Class I genes in human esophageal squamous cell carcinomas. Carcinogenesis 22:1615–1623.
   PubMed Web of Science ®Google Scholar
• Petersson, M., Charo, J., Salazar-Onfray, F., Noffz, G., Mohaupt, M., Qin, Z., Klein, G., Blankenstein, T., Kiessling, R. 1998. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC Class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J. Immunol. 161:2099–2105.
   PubMed Web of Science ®Google Scholar
• Ramal, L. M., Maleno, I., Cabrera, T., Collado, A., Ferron, A., Lopez-Nevot, M. A., Garrido, F. 2000. Molecular strategies to define HLA haplotype loss in microdissected tumor cells. Hum. Immunol. 61:1001–1012.
   PubMed Web of Science ®Google Scholar
• Ramnath, N., Tan, D., Li, Q., Hylander, B. L., Bogner, P., Ryes, L., Ferrone, S. 2006. Is down-regulation of MHC Class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol. Immunother. 55:891–899.
   PubMed Web of Science ®Google Scholar
• Reits, E. A., Hodge, J. W., Herberts, C. A., Groothuis, T. A., Chakraborty, M., Wansley, E. K., Camphausen, K., Luiten, R. M., de Ru, A. H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F. A., Spits, H., Schlom, J., van Veelen, P., Neefjes, J. J. 2006. Radiation modulates the peptide repertoire, enhances MHC Class I expression, and induces successful antitumor immunotherapy. J. Exp. Med. 203:1259–1271.
   PubMed Web of Science ®Google Scholar
• Rodriguez, T., Mendez, R., Del Campo, A., Jimenez, P., Aptsiauri, N., Garrido, F., Ruiz-Cabello, F. 2007. Distinct mechanisms of loss of IFNγ-mediated HLA Class I inducibility in two melanoma cell lines. BMC Cancer 7:34.
   PubMed Web of Science ®Google Scholar
• Seliger, B. 2005. Strategies of tumor immune evasion. BioDrugs 19:347–354.
   PubMed Web of Science ®Google Scholar
• Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Ehring, B., Tampe, R., Huber, C. 1996a. Reduced membrane major histocompatibility complex Class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin. Cancer Res. 2:1427–1433.
   PubMed Web of Science ®Google Scholar
• Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Meyer, T., Tampe, R., Momburg, F., Huber, C. 1996b. Analysis of the major histocompatibility complex Class I antigen presentation machinery in normal and malignant renal cells: Evidence for deficiencies associated with transformation and progression. Cancer Res. 56:1756–1760.
   PubMed Web of Science ®Google Scholar
• Seliger, B., Maeurer, M. J., Ferrone, S. 2000. Antigen-processing machinery breakdown and tumor growth. Immunol. Today 21:455–464.
   PubMedGoogle Scholar
• Seliger, B., Ritz, U., Abele, R., Bock, M., Tampe, R., Sutter, G., Drexler, I., Huber, C., Ferrone, S. 2001. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC Class I antigen processing pathway. Cancer Res. 61:8647–8650.
   PubMed Web of Science ®Google Scholar
• Seliger, B., Ritz, U., Ferrone, S. 2006. Molecular mechanisms of HLA Class I antigen abnormalities following viral infection and transformation. Int. J. Cancer 118:129–138.
   PubMed Web of Science ®Google Scholar
• Teoh, C. Y., Davies, K. J. 2004. Potential roles of protein oxidation and the immunoproteasome in MHC Class I antigen presentation: the ‘PrOxI’ hypothesis. Arch. Biochem. Biophys. 423:88–96.
   PubMed Web of Science ®Google Scholar
• Vertuani, S., De Geer, A., Levitsky, V., Kogner, P., Kiessling, R., Levitskaya, J. 2003. Retinoids act as multi-step modulators of the major histocompatibility Class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res. 63:8006–8013.
   PubMed Web of Science ®Google Scholar
• Vertuani, S., Dubrovska, E., Levitsky, V., Jager, M. J., Kiessling, R., Levitskaya, J. 2007. Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells. Cancer Immunol. Immunother. 56:193–204.
   PubMed Web of Science ®Google Scholar
• Yewdell, J. W. 2005. The seven dirty little secrets of major histocompatibility complex Class I antigen processing. Immunol. Rev. 207:8–18.
   PubMedGoogle Scholar
• Zhu, K., Wang, J., Zhu, J., Jiang, J., Shou, J., Chen, X. 1999. p53 induces TAP1 and enhances the transport of MHC Class I peptides. Oncogene 18:7740–7747.
   PubMed Web of Science ®Google Scholar